Clean Science and Technology Limited — PPTs, 31-01-2026: Investor Presentation

Clean Science and Technology reported Q3 FY26 consolidated revenue of 219 Cr, a 9% year-on-year decline, with Profit After Tax (PAT) at 46 Cr, down 30%. For the nine-month period, consolidated revenue was stable at 707 Cr (up 1%), though PAT decreased 10% to 171 Cr. The Performance Chemical segment, boosted by HALS series, saw its revenue share increase, and EBITDA margins proved resilient despite market challenges.

The company recently commercialized Hydroquinone and Catechol in Q3 FY26, aiming to accelerate future sales. Construction for Performance Chemical 2 is progressing as planned. The board approved an interim dividend of Rs. 2 per share. Strategic growth areas include ongoing greenfield capital expenditure for new products, adding advanced chemistries, and focusing on high-value speciality chemicals for diverse industries, all while maintaining a commitment to sustainable chemistry.